Chiasma's Mycapssa Associated With Positive Patient-Reported Outcomes In Acromegaly Patients

  • Chiasma Inc CHMA has presented patient-reported outcomes (PROs) data from its MPOWERED Phase 3 trial of Mycapssa for acromegaly, a hormonal disorder in which the pituitary gland produces too much growth hormone.
  • Data demonstrated that study patients reported significantly improved quality of life and work productivity after transitioning from long-acting injectable somatostatin analogs (iSSAs) to Mycapssa.
  • The data were presented at the Annual American Association of Clinical Endocrinology Meeting.
  • In the MPOWERED study, 146 patients entered the 6-month run-in phase in which all patients received Mycapssa.
  • 92 patients who were responders to Mycapssa at the end of run-in were then randomized into the 9-month randomized controlled treatment phase to receive Mycapssa or iSSAs.
  • Among the 92 randomized patients, results showed that several PROs, including quality of life and work productivity, were significantly improved at the end of the run-in phase (reflecting outcomes on Mycapssa) compared to their results at the baseline of run-in (reflecting outcomes on iSSAs).
  • The safety profile of Mycapssa in the MPOWERED trial was consistent with the known safety profile of octreotide but without adverse injection site reactions.
  • No new or unexpected safety signals were detected during the study.
  • Price Action: CHMA shares are up 0.23% at $4.29 during the premarket session on the last check Friday.

Posted In: AcromegalyBriefsBiotechNewsPenny StocksHealth CareGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.